Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREW Study of tezepelumab in chronic rhinosinusitis with nasal polyps in Japan
jRCT1030260434Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tezepelumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by AstraZeneca. Primary endpoint: Mean change from baseline in SNOT-22 total score at 24 weeks. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on jRCT1030260434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030260434.